Research ArticleClinical Investigations
Prospective Study of 3′-Deoxy-3′-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma
Heiko Schöder, Andrew D. Zelenetz, Paul Hamlin, Somali Gavane, Steven Horwitz, Matthew Matasar, Alison Moskowitz, Ariela Noy, Lia Palomba, Carol Portlock, David Straus, Ravinder Grewal, Jocelyn C. Migliacci, Steven M. Larson and Craig H. Moskowitz
Journal of Nuclear Medicine May 2016, 57 (5) 728-734; DOI: https://doi.org/10.2967/jnumed.115.166769
Heiko Schöder
1Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
Andrew D. Zelenetz
2Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and
Paul Hamlin
2Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and
Somali Gavane
1Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
Steven Horwitz
2Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and
Matthew Matasar
2Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and
Alison Moskowitz
2Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and
Ariela Noy
2Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and
Lia Palomba
2Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and
Carol Portlock
2Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and
David Straus
2Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and
Ravinder Grewal
1Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
Jocelyn C. Migliacci
3Department of Surgery, Memorial Sloan Kettering Cancer Center, New York
Steven M. Larson
1Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
Craig H. Moskowitz
2Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 5
May 1, 2016
Prospective Study of 3′-Deoxy-3′-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma
Heiko Schöder, Andrew D. Zelenetz, Paul Hamlin, Somali Gavane, Steven Horwitz, Matthew Matasar, Alison Moskowitz, Ariela Noy, Lia Palomba, Carol Portlock, David Straus, Ravinder Grewal, Jocelyn C. Migliacci, Steven M. Larson, Craig H. Moskowitz
Journal of Nuclear Medicine May 2016, 57 (5) 728-734; DOI: 10.2967/jnumed.115.166769
Prospective Study of 3′-Deoxy-3′-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma
Heiko Schöder, Andrew D. Zelenetz, Paul Hamlin, Somali Gavane, Steven Horwitz, Matthew Matasar, Alison Moskowitz, Ariela Noy, Lia Palomba, Carol Portlock, David Straus, Ravinder Grewal, Jocelyn C. Migliacci, Steven M. Larson, Craig H. Moskowitz
Journal of Nuclear Medicine May 2016, 57 (5) 728-734; DOI: 10.2967/jnumed.115.166769